Abstract
Background The HIV outbreak among People Who Inject Drugs (PWID) in Athens, Greece in 2011-2013 was the largest recent epidemic in Europe and North America. We aim to provide updated estimates of HIV prevalence and incidence.
Methods Two community-based HIV/hepatitis C programs on active PWID were implemented in 2012-2013 (ARISTOTLE, N=3,320) and 2018-2020 (ARISTOTLE HCV-HIV, N=1,635) through consecutive respondent-driven sampling recruitment rounds. PWID were uniquely identified across rounds/programs. We evaluated trends in HIV prevalence, socioeconomic characteristics, and injection practices in PWID participating in both periods and estimated HIV incidence in a cohort of seronegative PWID. Molecular sequencing and phylogenetic analysis were performed in HIV seroconverters.
Results HIV prevalence (95% CI) increased from 14.2% (11.7%-17.1%) in 2012-2013 to 22.0% (19.0%-25.3%) in 2018-2020 (p<0.001). There was a deterioration of socioeconomic characteristics such as homelessness (from 16.2% to 25.6%, p<0.001), a shift in the use of cocaine (from 16.6% to 28.1%, p<0.001), reduced access to free syringes (past 12 months: 51.8% and 45.1%, p=0.005) and to HIV testing (past 12 months: 50.9% and 49.4%). HIV incidence (95% CI) in 2014-2015, 2016-2017 and 2018-February 2020 was 2.10 (1.41-3.14), 2.04 (1.34-3.10) and 1.52 (0.84-2.75) new cases/100 person-years, respectively. Younger age, lower educational level, larger injection network and daily injecting were risk factors for HIV seroconversion. Almost 9% of HIV seroconversions occurred within a newly expanding phylogenetic cluster.
Conclusion The ongoing HIV transmission among PWID in Athens provides empirical evidence that the current levels of prevention and treatment are inadequate to control the epidemic, leading to expansion of the pool of infected PWID and a rise in HIV prevalence. Re-evaluation of prevention and treatment programs is urgently needed.
Funding European Union and Greek national funds, Gilead Sciences, AbbVie, Hellenic Scientific Society for the Study of AIDS, STDs and Emerging Diseases, MSD, and Gilead Hellas.
Competing Interest Statement
Conflict of interest statement VS has received a grant by Gilead Sciences and Abbvie for the submitted work. She has served as a lecturer for Gilead, Abbvie, and Janssen. DParaskevis has received grants from Gilead Sciences and GSK and participated in advisory boards of Gilead Sciences, GSK and MSD MPsichogiou has received a grant by Gilead Sciences, served as a lecturer for Gilead, Abbvie and MSD and participated in advisory boards for Gilead, Abbvie and MSD GK has received a grant by Gilead Sciences. AH has participated in advisory boards for Gilead, AbbVie, BMS and received unrestricted grants: from AbbVie, BMS, Gilead, MSD, Novartis. He is Co-Chair of Hepatitis B & C Public Policy Association funded by AbbVie, Gilead, and MSD. SR, EGK, EF, TA, SC, MPapadopoulou, IDP, MM, EH, MPylli, CT, DParaskeva, AB, have nothing to disclose.
Funding Statement
European Union and Greek national funds, Gilead Sciences, AbbVie, Hellenic Scientific Society for the Study of AIDS, STDs and Emerging Diseases, MSD, and Gilead Hellas.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The survey protocols and informed consent forms of the two programs were approved by the Institutional Review Boards of: i) the Medical School of the National and Kapodistrian University of Athens and ii) the Hellenic Scientific Society for the Study of AIDS, STDs and Emerging Diseases.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are not available for sharing.
